Your browser doesn't support javascript.
loading
Histologic features of melanoma associated with germline mutations of CDKN2A, CDK4, and POT1 in melanoma-prone families from the United States, Italy, and Spain.
Sargen, Michael R; Calista, Donato; Elder, David E; Massi, Daniela; Chu, Emily Y; Potrony, Míriam; Pfeiffer, Ruth M; Carrera, Cristina; Aguilera, Paula; Alos, Llucia; Puig, Susana; Elenitsas, Rosalie; Yang, Xiaohong R; Tucker, Margaret A; Landi, Maria Teresa; Goldstein, Alisa M.
  • Sargen MR; Clinical Genetics Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Rockville, Maryland. Electronic address: michael.sargen@nih.gov.
  • Calista D; Department of Dermatology, Maurizio Bufalini Hospital, Cesena, Italy.
  • Elder DE; Department of Pathology and Laboratory Medicine, Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania.
  • Massi D; Section of Pathological Anatomy, Department of Health Sciences, University of Florence, Florence, Italy.
  • Chu EY; Department of Dermatology, Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania.
  • Potrony M; Melanoma Unit, Dermatology Department, Hospital Clínic de Barcelona, Instituto de Investigaciones Biomédicas August Pi i Sunyer (IDIBAPS), Universitat de Barcelona, Barcelona, Spain; Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER), Barcelona, Spain.
  • Pfeiffer RM; Biostatistics Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Rockville, Maryland.
  • Carrera C; Melanoma Unit, Dermatology Department, Hospital Clínic de Barcelona, Instituto de Investigaciones Biomédicas August Pi i Sunyer (IDIBAPS), Universitat de Barcelona, Barcelona, Spain; Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER), Barcelona, Spain.
  • Aguilera P; Melanoma Unit, Dermatology Department, Hospital Clínic de Barcelona, Instituto de Investigaciones Biomédicas August Pi i Sunyer (IDIBAPS), Universitat de Barcelona, Barcelona, Spain; Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER), Barcelona, Spain.
  • Alos L; Pathology Department, Hospital Clínic de Barcelona, Universitat de Barcelona, Barcelona, Spain.
  • Puig S; Melanoma Unit, Dermatology Department, Hospital Clínic de Barcelona, Instituto de Investigaciones Biomédicas August Pi i Sunyer (IDIBAPS), Universitat de Barcelona, Barcelona, Spain; Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER), Barcelona, Spain.
  • Elenitsas R; Department of Dermatology, Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania.
  • Yang XR; Integrative Tumor Epidemiology Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Rockville, Maryland.
  • Tucker MA; Human Genetics Program, Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Rockville, Maryland.
  • Landi MT; Integrative Tumor Epidemiology Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Rockville, Maryland.
  • Goldstein AM; Clinical Genetics Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Rockville, Maryland.
J Am Acad Dermatol ; 83(3): 860-869, 2020 Sep.
Article en En | MEDLINE | ID: mdl-32283231
ABSTRACT

BACKGROUND:

CDKN2A, CDK4, and POT1 are well-established melanoma-susceptibility genes.

OBJECTIVE:

We evaluated melanoma histopathology for individuals with germline mutations of CDKN2A, CDK4, and POT1.

METHODS:

We assessed histopathology for melanomas diagnosed in melanoma-prone families (≥2 individuals with melanoma) from the United States, Italy, and Spain. Comparisons between mutation carriers and noncarriers (no mutation) were adjusted for age, sex, Breslow depth, and correlations among individuals within the same family.

RESULTS:

Histologic slides were evaluated for 290 melanomas (139 from 132 noncarriers, 122 from 68 CDKN2A carriers, 10 from 6 CDK4 carriers, and 19 from 16 POT1 carriers). Superficial spreading was the predominant subtype for all groups. Spitzoid morphology (>25% of tumor) was observed in 10 of 15 invasive melanomas (67%) from POT1 carriers (P < .0001 vs noncarriers). This finding was independently confirmed by 3 expert melanoma dermatopathologists in 9 of 15 invasive melanomas (60%). In situ and invasive melanomas from CDKN2A and CDK4 carriers were histologically similar to melanomas from noncarriers.

LIMITATIONS:

Limited sample sizes for rare melanoma-susceptibility syndromes (CDK4, POT1).

CONCLUSION:

Spitzoid morphology was associated with POT1 mutations suggesting that telomere dysfunction (POT1 mutations) may contribute to spitzoid differentiation in melanocytic tumors.
Asunto(s)
Palabras clave

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Piel / Neoplasias Cutáneas / Inhibidor p16 de la Quinasa Dependiente de Ciclina / Proteínas de Unión a Telómeros / Quinasa 4 Dependiente de la Ciclina / Melanoma Tipo de estudio: Clinical_trials / Risk_factors_studies Límite: Adult / Female / Humans / Male / Middle aged País como asunto: America do norte / Europa Idioma: En Año: 2020 Tipo del documento: Article

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Piel / Neoplasias Cutáneas / Inhibidor p16 de la Quinasa Dependiente de Ciclina / Proteínas de Unión a Telómeros / Quinasa 4 Dependiente de la Ciclina / Melanoma Tipo de estudio: Clinical_trials / Risk_factors_studies Límite: Adult / Female / Humans / Male / Middle aged País como asunto: America do norte / Europa Idioma: En Año: 2020 Tipo del documento: Article